CA19-9 – MMab


IHC of CA19-9 on an FFPE Salivary Gland Tissue

Specification Sheets
Safety Data Sheet
Intended UseFor In Vitro Diagnostic Use
Summary and ExplanationCA19-9 (carbohydrate antigen 19-9 or sialylated Lewis (a) antigen) is a blood test from the tumor marker category. It was discovered in patients with Colon Cancer and Pancreatic Cancer in 1981. Increased levels of CA19-9 are also found in non-malignant conditions, such as Mirizzi’s Syndrome and diseases of the bile duct and liver. The main use of CA19-9 is to determine whether a pancreatic tumor is secreting it; if that is the case, then the levels should fall when the tumor is treated, and they may rise again if the disease recurs. CA19-9 antigen is highly expressed in Gastrointestinal (gastric, pancreatic, and colonic) Adenocarcinomas and salivary gland Mucoepidermoid Carcinomas. CA19-9 is usually not reactive with breast, kidney, and prostate Carcinomas, but is reactive with sialylated Lea-active pentasaccharide (sialylated lacto-N-fucopentaose II), which is enzymatically synthesized by sialylation of Type 1 carbohydrate chains.
Antibody TypeMouse MonoclonalClone121SLE
IsotypeIgMReactivityParaffin, Frozen
LocalizationCytoplasmicControlBreast, Colon, Cervix, Pancreas, Pancreas Cancer, Breast Carcinoma, Colon Carcinoma, Transitional Cell Carcinoma, Ovarian Carcinoma Thyroid Carcinoma
PresentationCA19-9 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Catalog No.Antibody TypeDilutionVolume/QTY
BSB 5106PredilutedReady-To-Use3.0 ml
BSB 5107PredilutedReady-To-Use7.0 ml
BSB 5108PredilutedReady-To-Use15.0 ml
BSB 5109Concentrated1:100 – 1:5000.1 ml
BSB 5110Concentrated1:100 – 1:5000.5 ml
BSB 5111Concentrated1:100 – 1:5001.0 ml
BSB 5112Control Slides5
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.

Related products

Skip to content